Castle Biosciences, Inc. (CSTL) Dividend History

Castle Biosciences, Inc. is a dermatologic oncology company focused on developing assays that assist in diagnosing, prognosing, and managing skin cancer. The company specializes in providing molecular diagnostic tests aimed at improving clinical decision-making and patient care for various skin cancers, including melanoma and dermatologic conditions. Founded in 2010, Castle Biosciences is committed to advancing personalized medicine through innovative diagnostic technologies.

505 S Friendswood Drive, Friendswood, TX, 77546
Phone: 866-788-9007
Website: https://www.castlebiosciences.com

Dividend History

Castle Biosciences, Inc. currently does not pay dividends

Company News

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences is supporting initiatives to raise awareness and educate patients about skin cancer, including partnering with IMPACT Melanoma, AIM at Melanoma, and Melanoma Research Foundation. The company is also sharing the story of melanoma survivor Leah Adams and her experience with the DecisionDx-Melanoma test.

GlobeNewswire Inc.
Castle Biosciences to Acquire Previse

Castle Biosciences, a diagnostics company, has signed a definitive agreement to acquire Previse, a gastrointestinal health company. The acquisition is expected to complement Castle's current gastroenterology franchise and expand its offerings within the GI vertical.

Benzinga
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

A new study shows that Castle Biosciences' DecisionDx-Melanoma test outperforms standard staging and another genomic test in identifying patients with a low risk of sentinel lymph node positivity, potentially allowing them to safely forgo the associated surgical procedure.

GlobeNewswire Inc.
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

A study published in the World Journal of Surgical Oncology and Cancer Medicine shows that Castle Biosciences' DecisionDx-Melanoma test can accurately identify patients with low risk of sentinel lymph node positivity, allowing them to safely forgo the biopsy procedure without experiencing disease progression.

GlobeNewswire Inc.
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology

The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.

GlobeNewswire Inc.

Featured Companies: A BDX BIO BIO.B GH ILMN MYGN NEO PKI PSNL QGEN SGMO TEM TMO TWST

Dividend data last updated 06/07/2025 16:09:16 UTC